Better MDS care through a national patient registry
Part of Blood & lymphatic clinical trials.
This study is building a national platform in Spain to better understand MDS (a bone marrow disorder) and to help tailor treatments to each person. By joining, you help researchers learn more about your condition and how to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed MDS diagnosis based on lab tests.
- Your medical team has all your relevant health records.
- You are willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses repeated blood samples to watch how genetic changes in your blood evolve in lower-risk myelodysplastic syndrome (MDS). It may help doctors understand what mutation changes mean over time for people not on strong cancer-fighting treatments.
This study is a database that collects information from people diagnosed with myelodysplastic syndromes. It may help researchers better understand the condition and how patients do over time.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This study collects information from people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that developed after cancer treatment. It does not test a new drug but helps doctors learn more about these conditions.
This trial collects and stores biological samples (like blood or other lab materials) from people with myelodysplastic syndrome, to help researchers learn more about the disease. It may help future diagnosis or treatments, even if it doesn’t directly test a new medicine.
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.